January 21, 2022
PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
National Cancer Institute (NCI)
As part of the Cancer Moonshot initiative, the National Cancer Institute (NCI) created the Patient-Derived Xenograft (PDX) Research Network (PDXNet), a collaborative network of U54-funded PDX Development and Trial Centers (PDTCs) of excellence coordinated by a U24-funded PDXNet Data Commons and Coordinating Center (PDCCC) focused on using patient-derived xenografts and other patient-derived models to accelerate the development of NCI investigational new drug (IND) agents (i.e., those that the NCI is developing in collaboration with pharmaceutical partners) in NCI-sponsored early phase clinical trials. Because PDXNet investigators have valuable models and specialized expertise not usually accessible to most investigators, NCI through this Notice of Special Interest (NOSI) intends to make the resources of these centers available to other investigators to test novel therapeutic concepts.
Research Objectives
This NOSI will support supplemental funds to current NCI-funded research projects in PDXNet for new interdisciplinary collaborations between PDXNet investigators and non-PDXNet investigators. Non-PDXNet investigators include physician scientists in NCI-funded clinical trials networks. These collaborations should perform research within the scientific scope(s) of the cooperative agreement award, to include pre-clinical evaluations of novel therapeutic concepts using the large-scale PDX model collections of PDXNet for translation into clinical trial concepts. This request for administrative supplements supports NCI’s efforts to enhance the development of PDX models as a tool for precision medicine that will guide cancer drug development and cancer therapy. The research project proposed in the administrative supplement should align with the overarching goal of the PDXNet, which is to develop pre-clinical data to support novel therapeutic concepts that have a feasible path for clinical validation.
Responsiveness
A subcontract award from the PDXNet investigator’s institution may be used to fund research conducted by the non-PDXNet collaborating investigator under this administrative supplement. A collaboration that involves a subcontract should describe research performed by both the collaborator and the PDXNet investigator. The non-PDXNet collaborator may commit to translating the research results into a clinical trial concept based on the data generated under the supplement award should these data be supportive of the concept.
Applicants are encouraged to discuss their application with the scientific/research contact listed in this NOSI prior to submission.
Application and Submission Information
Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.
All instructions in the SF424 (R&R) Application Guide and PA-20-272 must be followed, with the following additions:
Submitting Applications:
Review and Selection Process
NCI will conduct administrative reviews of applications and will support the most meritorious applications submitted for consideration, based upon availability of funds. Additionally, Program staff will evaluate applications using the following selection factors.
NIH staff will consider the ability of the proposed supplement activities to increase or preserve the PDXNet award’s overall impact within the original scope of the award, including the degrees to which the administrative supplement request (application):
• Tests therapeutic concepts using the large-scale PDXNet model collections, especially concepts that require identification of molecularly defined subsets of histologically defined tumors
• Identifies potential biomarkers that could be used to monitor or select patients for therapy
• Identifies underlying genetic or epigenetic variations that could explain different therapeutic responses between racial/ethnic minority patient populations (if applying for a Minority-PDTC collaboration)
• Outlines an interactive collaboration between the PDXNet investigator and the non-PDXNet investigator
Kim Witherspoon
National Cancer Institute (NCI)
Telephone: 240-276-6141
Email: kw265c@nih.gov
Jeffrey Moscow, M.D.
PDXNet Program Official
National Cancer Institute (NCI)
Telephone: 240-276-6565
Email: jeffrey.moscow@nih.gov
Tiffany Wallace, Ph.D.
M-PDTC Program Officer
National Cancer Institute (NCI)
Telephone: 240-276-5114
Email: Tiffany.Wallace@nih.gov